Form 4: MAIA Biotechnology Director Ramiro Guerrero Reports Stock Option Grant

Director Ramiro Guerrero reports acquisition of 5,728 stock options in MAIA Biotechnology, Inc.

Summary

• Ramiro Guerrero, a director of MAIA Biotechnology, Inc., filed a Form 4 on July 2, 2024, reporting a transaction.
• The transaction involved the acquisition of 5,728 stock options on June 30, 2024.
• These options, granted under the company's 2021 Equity Incentive Plan, have an exercise price of $3.42.
• The options vest immediately and are exercisable from the grant date, with an expiration date of June 30, 2034.
• Following the transaction, Guerrero directly owns 5,728 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction related to executive compensation. It's neither overwhelmingly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• Immediate vesting of the options could incentivize the director to contribute to the company's success.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• It incentivizes the director, which could positively impact the company's performance and thus benefit all stakeholders.

Key Dates